Sanofi-Aventis Enters First R&D Pact In India, For Glenmark's Pain Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Lead candidate, GRC 15300, is in Phase I for diabetic neuropathic pain and osteoarthritric pain.
You may also be interested in...
Sanofi-Aventis India Managing Director Shailesh Ayyangar On Building Infrastructure In India To Bring Affordable Drugs To Patients In Rural Markets: An Interview With PharmAsia News (Part 1 of 2)
Sanofi-Aventis has had an interesting past in India from having a discovery research center to creating some of the most recognized pharmaceutical brands. But its Managing Director Shailesh Ayyangar is not resting on those achievements. The senior executive who started with Ranbaxy and also worked at SmithKline Beecham in key positions is now taking up the daunting challenge of creating a new paradigm in the rural centers of India. An exercise that requires huge investments, navigation of unseen opposition along with perseverance to witness a real change excites Ayyangar. In a rare interview, Ayyangar spoke to PharmAsia News' India Bureau about the company's rural markets strategy, creating brands, doing research deals and also about buying out "strategically important" companies.
Lilly Acquires Rights To TRPV-1 Receptor Antagonists From Glenmark
Eli Lilly is gaining a portfolio of molecules targeting the vanilloid-1 receptor, including Phase II candidate GRC 6211, through an agreement with Mumbai, India-based Glenmark Pharmaceuticals, announced Oct. 30
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.